B+
Bull case
25%
Probability
Target price
$6.50
+29.7% vs current
ZNTL
ZentalisCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-21
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$4.50
-10.2% vs current
B-
Bear case
30%
Probability
Target price
$1.80
-64.1% vs current
AI sentiment snapshot
Latest data as of 2026-06-18
Recent news sentiment (30D)
+55.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Sentiment proxy
+31.0
Score
AI commentary
Primary-source tone is constructive because March and May 2026 company filings confirmed dose selection, ASPENOVA initiation, and cash runway into late 2027, but the evidence base is still mostly company-controlled and filing-led. There is no trusted recent-news packet, no analyst-revision detail, and no usable social-coverage signal here, so the setup remains a cautious monitoring view rather than a confirmed rerating thesis.
RankAlpha Sentiment Codex - 2026-06-18
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-09-30catalystCash runway limits immediate financing pressureMedium impact
Zentalis reported $211.8 million of cash, cash equivalents and marketable securities as of March 31, 2026 and said that runway extends into late 2027, which supports execution through key ovarian-cancer milestones but does not remove burn risk for a precommercial biotech [#SEC-8K-2026-05-12].
2026-12-31eventASPENOVA execution can de-risk the registration pathHigh impact
Management said ASPENOVA, the Phase 3 confirmatory trial in Cyclin E1-positive PROC, has been initiated with first patient dosed and is intended to support full approval and ex-US registrations, so visible enrollment and operational progress through 2H 2026 would help validate the broader approval strategy [#SEC-8K-2026-05-12].
2026-12-31catalystDENALI Part 2 topline remains the decisive rerating eventHigh impact
The company continues to guide to a DENALI Phase 2 topline readout by year-end 2026, with potential relevance to an accelerated approval pathway subject to data outcomes and FDA feedback; for ZNTL this remains the core binary value driver [#SEC-8K-2026-05-12][#SEC-8K-2026-03-26][#PR-EARNINGS-2026-05-12].
Recommendation
N/A
No formal recommendation provided.
As of 2026-06-18 • Updated nightlySource: Internal modelMethodology